Compare Amgen, Inc. (AMGN) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs T-Mobile Us Inc — how do they compare? Amgen, Inc. trades at $360.06 (market cap $196.12B), while T-Mobile Us Inc trades at $190.02 (market cap $203.03B). The key difference: Amgen, Inc. and T-Mobile Us Inc are close in size by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | TMUS | |
|---|---|---|
Market Cap | $196.12B | $203.03B |
Sector | Health | Media |
52-Week High | $388.16 | $259.01 |
52-Week Low | $271.18 | $167.65 |
Enterprise Value | $241.41B | $320.73B |
Dividend Yield | 2.77% | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
T-Mobile US (TMUS) trades at $187.61, up 3.38% on the day, with a neutral technical signal and strong analyst support. The stock shows robust fundamentals with 2025 revenue of $88.31B, net income of $10.99B, and consistent cash flow generation. Recent leadership changes and competitive threats from SpaceX's potential market entry are key developments. Valuation metrics include a P/E of 19.94 and P/S of 2.32, while the consensus price target is $244.50, suggesting significant upside potential.
The outlook for TMUS is positive due to strong earnings beats, healthy profitability margins, and growth in postpaid accounts. Risks include rising debt levels, intense competition, and capital expenditure pressures. With 83% of analysts rating it a Buy, the stock presents a compelling opportunity for long-term investors, though monitoring competitive dynamics and interest expense trends is crucial.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
